Equivalent detection of genotypes 1-6

Fig 1. Relative recovery of non-1a HCV genotype transcripts compared to that of the genotype 1a transcript. Transcripts were tested at two concentrations.¹

The VERSANT HCV RNA 3.0 assay (bDNA) helps laboratories reduce their biggest expense: labor.

VERSANT HCV RNA 3.0 Assay (bDNA) accurately quantitates throughout its broad dynamic range.

• Broad dynamic range (615 to 7,690,000 IU/mL) dramatically reduces repeat testing
  Saves time, costs, and provides the ability to detect a clinically significant 2-log drop in viral load
• No viral extraction
  Eliminates tedious extraction steps (required with PCR assays) that increase risk of cross-contamination

• Minimal hands-on time - Requires only one laboratory technologist
• Familiar ELISA-like format - Easy to learn and master

• One-room technology - Eliminates need for separate, dedicated clean room necessary for PCR methods

References
1. Elbeik, T et al. 2004. Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCV RNA 3.0 Assay (bDNA). JCM, 42(2); 563-569.

COBAS is a trademark of Roche Group.